Table 2.

Correlations between PFS and patient and tumor characteristics.

	Univariate analysis		P value	Multivariate analysis		P value
	Hazard ratio	95% CI		Hazard ratio	95% CI
Age (>59 years)	0.911	0.709–1.171	0.467
Sex (male)	1.051	0.806–1.370	0.715
Body mass index (<18.5 or >25 kg/m2)	0.971	0.731–1.292	0.842
ECOG PS score (>1)	0.929	0.657–1.313	0.675
Pathological differentiation (poorly)	1.197	0.902–1.590	0.214
The number of organs affected by metastasis (>1)	1.511	1.161–1.967	0.002	1.299	0.954–1.768	0.096
Peritoneal metastasis (Yes)	1.506	1.144–1.983	0.004	1.147	0.822–1.602	0.419
TNM staging (IV)	1.375	1.009–1.875	0.044	1.017	0.720–1.436	0.924
CEA (>5 ng/mL)	1.240	0.959–1.604	0.101	1.134	0.857–1.501	0.377
CA19-9 (>37 U/mL)	0.925	0.713–1.200	0.558
CA72-4 (>6 U/mL)	1.479	1.143–1.914	0.003	1.241	0.941–1.636	0.126
Thrombocyte counts (>300 × 109/L)	1.100	0.843–1.435	0.483
ADR (≥41.64)	0.445	0.338–0.585	<0.001	0.509	0.380–0.681	<0.001

ADR, albumin to D-dimer ratio; ECOG PS, eastern cooperative oncology group performance status; CEA, carcinoembryonic antigen; CA72-4, carbohydrate antigen 72-4; CA19-9, carbohydrate antigen 19-9; CI, confidence interval; PFS, progressive-free survival.